- Home
- DNN vs RCUS Comparison
DNN vs RCUS Comparison
Compare DNN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNN
- RCUS
- Stock Information
- Founded
- DNN 1936
- RCUS 2015
- Country
- DNN Canada
- RCUS United States
- Employees
- DNN N/A
- RCUS N/A
- Industry
- DNN Other Metals and Minerals
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- DNN Basic Materials
- RCUS Health Care
- Exchange
- DNN Nasdaq
- RCUS Nasdaq
- Market Cap
- DNN 1.7B
- RCUS 1.4B
- IPO Year
- DNN 1997
- RCUS 2018
- Fundamental
- Price
- DNN $2.25
- RCUS $17.96
- Analyst Decision
- DNN Strong Buy
- RCUS Buy
- Analyst Count
- DNN 2
- RCUS 12
- Target Price
- DNN $3.00
- RCUS $34.50
- AVG Volume (30 Days)
- DNN 23.5M
- RCUS 616.1K
- Earning Date
- DNN 11-07-2024
- RCUS 11-06-2024
- Dividend Yield
- DNN N/A
- RCUS N/A
- EPS Growth
- DNN N/A
- RCUS N/A
- EPS
- DNN N/A
- RCUS N/A
- Revenue
- DNN $2,920,167.00
- RCUS $263,000,000.00
- Revenue This Year
- DNN $272.08
- RCUS $127.13
- Revenue Next Year
- DNN $77.80
- RCUS N/A
- P/E Ratio
- DNN N/A
- RCUS N/A
- Revenue Growth
- DNN N/A
- RCUS 119.17
- 52 Week Low
- DNN $1.40
- RCUS $13.52
- 52 Week High
- DNN $2.47
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- DNN 52.27
- RCUS 65.13
- Support Level
- DNN $2.12
- RCUS $16.83
- Resistance Level
- DNN $2.37
- RCUS $18.09
- Average True Range (ATR)
- DNN 0.12
- RCUS 0.97
- MACD
- DNN -0.02
- RCUS 0.30
- Stochastic Oscillator
- DNN 37.14
- RCUS 96.70
About DNN Denison Mines Corp (Canada)
Denison Mines Corp is a uranium exploration and development company with interests focused in the Athabasca Basin region of northern Saskatchewan, Canada. The company has an effective 95% interest in its flagship Wheeler River Uranium Project, which is the largest undeveloped uranium project in the infrastructure-rich eastern portion of the Athabasca Basin region of northern Saskatchewan. The company is also engaged in mine decommissioning and environmental services through its Closed Mines group, which manages its Elliot Lake reclamation projects and provides third-party post-closure mine care and maintenance services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.